Skip to main content


Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma

Fig. 1

Combination effects of NVP-Bez235 and lenalidomide in proliferation inhibition. a, b Cell viability of Su-DHL2, OCI-Ly3, and OCI-Ly10 was measured by CCK-8 assay after treated with NVP-Bez235 and lenalidomide alone or in combination for 72 h. Drugs were conducted simultaneously at the indicated concentrations. c Isobologram analysis of agent combination at ED50 and CI values were calculated as well. d CI values of all cell lines at ED25, ED50, ED75 and ED90. The lower CI values indicated the stronger synergism when CI < 1, and higher CI values means the stronger antagonism when CI >1. Additive effect was designated with CI = 1

Back to article page